TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23742222

Group type: EXPERIMENTAL
Intervention: Aerobic training (10-week program, 3 sessions per week, 30-40 min treadmill exercise at 55-65% peak heart rate)
Number of subjects: 20
Study: 22483675

Group type: EXPERIMENTAL
Intervention: Dose-escalation to the entire primary tumour (arm A)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dose-escalation to the high FDG uptake region inside the primary tumour (arm B)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dose-escalation to the primary tumour (arm A)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dose-escalation to the boost region
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dose-limiting constraints
Number of subjects: 20
Study: 20211036

Group type: EXPERIMENTAL
Intervention: Combination of enteral nutrition (EN) with parenteral nutrition (PN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Parenteral nutrition (PN) alone
Number of subjects: 0
Study: 18540460

Group type: EXPERIMENTAL
Intervention: Infusion therapy with crystalloidal solutions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of crystalloidal solutions and a colloidal agent in a 1:1 ratio
Number of subjects: 0

Group type: COMPARATOR
Intervention: Infusion therapy with physiological sodium chloride
Number of subjects: 0
Study: 15763449

Group type: EXPERIMENTAL
Intervention: Allergic asthma
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Non-allergic asthma
Number of subjects: 23

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 23
Study: 12444337

Group type: EXPERIMENTAL
Intervention: Combination ointment (calcipotriol/betamethasone dipropionate)
Number of subjects: 1603

Group type: COMPARATOR
Intervention: Betamethasone dipropionate ointment
Number of subjects: 1603

Group type: COMPARATOR
Intervention: Calcipotriol ointment
Number of subjects: 1603

Group type: COMPARATOR
Intervention: Ointment vehicle
Number of subjects: 1603

Group type: EXPERIMENTAL
Intervention: Combination ointment
Number of subjects: 1603

Group type: COMPARATOR
Intervention: Betamethasone
Number of subjects: 1603

Group type: COMPARATOR
Intervention: Calcipotriol
Number of subjects: 1603
Study: 10522983

Group type: EXPERIMENTAL
Intervention: High isoflavone (high‐iso) diet
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Low isoflavone (low‐iso) diet
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 18
Study: 8540720

Group type: EXPERIMENTAL
Intervention: 150 mg ranitidine twice a day
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 300 mg ranitidine twice a day
Number of subjects: 15

Group type: COMPARATOR
Intervention: No ranitidine
Number of subjects: 15
Study: 1780078

Group type: EXPERIMENTAL
Intervention: Heparan sulfate (200 mg/die, 1 tablet in the morning and evening)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sulodexide (500 ULS/die, 1 capsule in the morning and evening)
Number of subjects: 40
Study: 6112387

Group type: EXPERIMENTAL
Intervention: A single dose of 300 mg aspirin taken 14 h preoperatively
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: A single dose of 81 mg aspirin taken 14 h preoperatively
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: A single dose of 40 mg aspirin taken 14 h preoperatively
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: A single dose of 300 mg aspirin
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: A single dose of 40 mg aspirin
Number of subjects: 68
Study: 31631500

Group type: EXPERIMENTAL
Intervention: CAD/CAM resin composite inlay (Lava Ultimate)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Direct resin composite (Clearfil Majesty Posterior)
Number of subjects: 44
Study: 28402747

Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg orally
Number of subjects: 131

Group type: COMPARATOR
Intervention: Paclitaxel (80 mg/m2 days 1, 8, and 15 every 28 days)
Number of subjects: 131
Study: 24878589

Group type: EXPERIMENTAL
Intervention: Arm support (AS) training combined with computerized exercises
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional reach training (CON)
Number of subjects: 70
Study: 23175270

Group type: EXPERIMENTAL
Intervention: Liquid-based cytology (LBC)
Number of subjects: 20627

Group type: EXPERIMENTAL
Intervention: Liquid-based cytology with computer-assisted imaging technology (LBC/CAS)
Number of subjects: 20627

Group type: COMPARATOR
Intervention: Conventional cytology (CC)
Number of subjects: 20627
Study: 21047620

Group type: EXPERIMENTAL
Intervention: Individually-tailored Internet-based treatment for anxiety disorders over 10 weeks with online therapist guidance.
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 54
Study: 18331938

Group type: EXPERIMENTAL
Intervention: Deep overbite correction treatment in mesofacial and brachyfacial subjects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Deep overbite correction treatment
Number of subjects: 0
Study: 16552403

Group type: EXPERIMENTAL
Intervention: Supernatant of 3T3-L1 cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supernatant of 3T3-L1 cells treated with HGF siRNA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supernatant of 3T3-L1 cells conditioned with pioglitazone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pioglitazone treatment in patients
Number of subjects: 0
Study: 14636839

Group type: EXPERIMENTAL
Intervention: Tramadol (50 mg three times a day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Paracetamol (500 mg three times a day)
Number of subjects: 20
Study: 10761354

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8822764

Group type: EXPERIMENTAL
Intervention: Fluoxetine (60 mg/day)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 1423087

Group type: EXPERIMENTAL
Intervention: Annual mammography and physical examination (MP group)
Number of subjects: 50430

Group type: COMPARATOR
Intervention: Usual care after an initial physical examination (UC group)
Number of subjects: 50430
Study: 3917315

Group type: EXPERIMENTAL
Intervention: Methimazole 30 mg + thyroxine 0.15 mg daily
Number of subjects: 10

Group type: COMPARATOR
Intervention: Thyroxine 0.15 mg alone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Methimazole followed by thyroxine 0.15 mg alone
Number of subjects: 10
Study: 31513248

Group type: EXPERIMENTAL
Intervention: 3 months of adjuvant oxaliplatin-based chemotherapy
Number of subjects: 1313

Group type: COMPARATOR
Intervention: 6 months of adjuvant oxaliplatin-based chemotherapy
Number of subjects: 1313

Group type: EXPERIMENTAL
Intervention: 3 months of adjuvant chemotherapy
Number of subjects: 1313

Group type: COMPARATOR
Intervention: 6 months of adjuvant chemotherapy
Number of subjects: 1313

Group type: EXPERIMENTAL
Intervention: CAPOX (3-month arm)
Number of subjects: 1313

Group type: COMPARATOR
Intervention: mFOLFOX6 (3-month arm)
Number of subjects: 1313

Group type: EXPERIMENTAL
Intervention: CAPOX (6-month arm)
Number of subjects: 1313

Group type: COMPARATOR
Intervention: mFOLFOX6 (6-month arm)
Number of subjects: 1313
Study: 29849515

Group type: EXPERIMENTAL
Intervention: Community-based occupational therapy program (6 weeks)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Usual activities of societies (control group)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Engagement in meaningful activities
Number of subjects: 21
Study: 26528636

Group type: EXPERIMENTAL
Intervention: Baseline galectin‐3 (≥17.8ng/mL)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Median values of galectin‐3 (13.4ng/mL)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Baseline sST2 (≥35.0ng/mL)
Number of subjects: 247
Study: 25237670

Group type: EXPERIMENTAL
Intervention: Platform Switching (PS) implants
Number of subjects: 18

Group type: COMPARATOR
Intervention: Regular Platform (RP) implants
Number of subjects: 18
Study: 23348814

Group type: EXPERIMENTAL
Intervention: 1 dose of MenACWY-TT at 12 months of age (ACWY-1 group)
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: 2 doses of MenACWY-TT at 9 and 12 months (ACWY-2 group)
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Both ACWY-1 and ACWY-2 groups
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Both schedules (ACWY-1 and ACWY-2)
Number of subjects: 349
Study: 20492047

Group type: EXPERIMENTAL
Intervention: Listening to music for 30 minutes, three times over two days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Rest periods for 30 minutes, three times over two days (Control)
Number of subjects: 20
Study: 18385123

Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation (PVI) for paroxysmal AF
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (LVEF > 50%)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: PVI for paroxysmal AF
Number of subjects: 70
Study: 16371487

Group type: EXPERIMENTAL
Intervention: Therapeutic medially directed tape
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo vertically directed tape
Number of subjects: 22

Group type: COMPARATOR
Intervention: No tape
Number of subjects: 22
Study: 12843003

Group type: EXPERIMENTAL
Intervention: Persistently elevated thrombin generation (measured by plasma prothrombin fragment 1 + 2 levels)
Number of subjects: 319
Study: 11176760

Group type: EXPERIMENTAL
Intervention: Risedronate
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Risedronate (low dose 2.5 mg)
Number of subjects: 9
Study: 9625541

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% once daily
Number of subjects: 36

Group type: COMPARATOR
Intervention: Timolol 0.5% twice daily
Number of subjects: 36
Study: 7875811

Group type: EXPERIMENTAL
Intervention: Intraosseous (IO) route for fluid infusion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous (IV) route for fluid infusion
Number of subjects: 60
Study: 3345044

Group type: EXPERIMENTAL
Intervention: Oral sustained-release theophylline
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30968604

Group type: EXPERIMENTAL
Intervention: Cisplatin (Cisplatin-100 mg/m2 q3w x 3)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Cisplatin-paclitaxel (Cisplatin-20 mg/m2; Paclitaxel-30 mg/m2 qw x 7)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Cisplatin
Number of subjects: 225

Group type: COMPARATOR
Intervention: Cisplatin-paclitaxel
Number of subjects: 225
Study: 28327892

Group type: EXPERIMENTAL
Intervention: TachoSil
Number of subjects: 726
Study: 25387260

Group type: EXPERIMENTAL
Intervention: Weekly testosterone administration (100 mg T enanthate, im injection, n = 5)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Monthly testosterone administration (alternating months of T and placebo, n = 7)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (n = 7)
Number of subjects: 19
Study: 24238792

Group type: EXPERIMENTAL
Intervention: Naloxegol 25 mg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Naloxegol 150 mg
Number of subjects: 52

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 21683023

Group type: EXPERIMENTAL
Intervention: Prime Time intervention
Number of subjects: 0
Study: 19466920

Group type: EXPERIMENTAL
Intervention: Forward stage transition
Number of subjects: 0

Group type: COMPARATOR
Intervention: No forward stage transition
Number of subjects: 0
Study: 16423667

Group type: EXPERIMENTAL
Intervention: Doppler tissue echocardiography and cardiac magnetic resonance with delayed gadolinium (Gd) gadopentetate dimeglumine (DTPA) contrast hyperenhancement
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 30
Study: 15673998

Group type: EXPERIMENTAL
Intervention: Self-selected homeopathic medicine
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Treatment by homeopaths
Number of subjects: 420

Group type: COMPARATOR
Intervention: Waiting list control using self-selected conventional health care
Number of subjects: 420

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 420
Study: 11728348

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 0
Study: 9224465

Group type: EXPERIMENTAL
Intervention: Humphrey automated visual field testing
Number of subjects: 106
Study: 7962336

Group type: EXPERIMENTAL
Intervention: L-T4 therapy
Number of subjects: 310

Group type: COMPARATOR
Intervention: TGPO aAb
Number of subjects: 310
Study: 31302851

Group type: EXPERIMENTAL
Intervention: Guanxinning Tablet (GXN), 4 tablets (0.38 g/tablet), thrice daily for 12 weeks
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo (Guanxinning simulation tablets, mainly composed of lactose), 4 tablets (0.38 g/tablet), thrice daily for 12 weeks
Number of subjects: 160
Study: 30051690

Group type: EXPERIMENTAL
Intervention: Mindfulness-based group training (8 sessions of 90 minutes each, twice a week for 1 month)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 66
Study: 26999528

Group type: EXPERIMENTAL
Intervention: Zero-profile implant (Zero-P)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Cages with plate fixation
Number of subjects: 72
Study: 23252417

Group type: EXPERIMENTAL
Intervention: Simulated barefoot running (SBR)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Shod running
Number of subjects: 15
Study: 22397512

Group type: EXPERIMENTAL
Intervention: Mortality reminders
Number of subjects: 294

Group type: COMPARATOR
Intervention: Control conditions
Number of subjects: 294
Study: 20187135

Group type: EXPERIMENTAL
Intervention: Combination etanercept-methotrexate therapy (EM/EM group, n = 111)
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Etanercept monotherapy (EM/E group, n = 111)
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Combination therapy (M/EM group, n = 90)
Number of subjects: 398

Group type: COMPARATOR
Intervention: MTX monotherapy (M/M group, n = 99)
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Combination etanercept-methotrexate therapy (EM/EM group)
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Etanercept monotherapy (EM/E group)
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Combination therapy (M/EM group)
Number of subjects: 398

Group type: COMPARATOR
Intervention: MTX monotherapy (M/M group)
Number of subjects: 398
Study: 18576924

Group type: EXPERIMENTAL
Intervention: Combination of oral administration of C. aurantium L. extracts and auricular acupressure
Number of subjects: 10

Group type: COMPARATOR
Intervention: Oral administration of C. aurantium L. extracts
Number of subjects: 10
Study: 16011397

Group type: EXPERIMENTAL
Intervention: Cigarette smoking cessation intervention (n = 26)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (n = 28)
Number of subjects: 54
Study: 12183860

Group type: EXPERIMENTAL
Intervention: Angioplasty + Stenting (AS)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Coronary Bypass Surgery (CABG)
Number of subjects: 96
Study: 10365642

Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Number of subjects: 11
Study: 7863967

Group type: EXPERIMENTAL
Intervention: Aspirin (75 mg) and Warfarin (dosed to an INR of 1.5)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin and Warfarin combination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin alone or Warfarin alone
Number of subjects: 0
Study: 1645768

Group type: EXPERIMENTAL
Intervention: Lisinopril (10-40 mg once a day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Captopril (25-100 mg twice a day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Office sphygmomanometry measurements
Number of subjects: 0
Study: 7294038

Group type: EXPERIMENTAL
Intervention: Cefoxitin sodium therapy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Clindamycin phosphate plus amikacin sulfate therapy
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Cefoxitin plus amikacin therapy
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Gentamicin sulfate and tobramycin sulfate (substituted for amikacin sulfate)
Number of subjects: 70
Study: 30282487

Group type: EXPERIMENTAL
Intervention: Results-based financing
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Non-results-based financing
Number of subjects: 3000
Study: 28853202

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 20 mg/kg/d
Number of subjects: 40
Study: 26953758

Group type: COMPARATOR
Intervention: 4-day antibiotic therapy (n = 72)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Longer antibiotic therapy (n = 57)
Number of subjects: 129
Study: 25438394

Group type: EXPERIMENTAL
Intervention: Fighting Obesity Campaign
Number of subjects: 2038
Study: 23253201

Group type: EXPERIMENTAL
Intervention: Family-skills training intervention consisting of eight parent and four youth sessions targeting parenting skills and parent-youth relational factors.
Number of subjects: 336

Group type: COMPARATOR
Intervention: Delayed treatment condition (control group).
Number of subjects: 336
Study: 19841330

Group type: EXPERIMENTAL
Intervention: Gemcitabine (GEM)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Mitomycin (MMC)
Number of subjects: 120
Study: 17681259

Group type: EXPERIMENTAL
Intervention: Biofield treatments delivered from a short distance for a total of 30 minutes before and after exposure to hydrogen peroxide.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group with no healing intervention.
Number of subjects: 24
Study: 16244030

Group type: EXPERIMENTAL
Intervention: Small-volume fluid management (8 mL.kg(‐1).h(‐1))
Number of subjects: 253

Group type: COMPARATOR
Intervention: Large-volume fluid management (16-18 mL.kg(‐1).h(‐1))
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Small-volume fluid management
Number of subjects: 253

Group type: COMPARATOR
Intervention: Large-volume fluid management
Number of subjects: 253
Study: 11894174

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary angioplasty (PTCA) with stents
Number of subjects: 136
Study: 9527071

Group type: EXPERIMENTAL
Intervention: Ongoing daily therapy of 50 mg aspirin and 400 mg dipyridamole
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Corrected TIMI frame counts < or = 27
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Corrected TIMI frame count and stenosis severity
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Stenosis severity at 4 weeks
Number of subjects: 154
Study: 10150852

Group type: EXPERIMENTAL
Intervention: Combined cataract and glaucoma surgery using small-incision extracapsular cataract extraction (ECCE) with phacoemulsification (PHACO)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Injections of 5-fluorouracil postoperatively
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intraoperative mitomycin C application in PHACO-ECCE-trabeculectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mitomycin C application
Number of subjects: 0
Study: 2214100

Group type: EXPERIMENTAL
Intervention: Intrapleural instillation of 1500 mg of tetracycline hydrochloride
Number of subjects: 229

Group type: COMPARATOR
Intervention: Control group (no tetracycline)
Number of subjects: 229
Study: 646248

Group type: EXPERIMENTAL
Intervention: Rapid smoking
Number of subjects: 24
Study: 31582314

Group type: EXPERIMENTAL
Intervention: BDP/FF/G (100 μg BDP, 6 μg FF, and 10 μg G)
Number of subjects: 1155

Group type: EXPERIMENTAL
Intervention: BDP/FF/G (200 μg BDP, 6 μg FF, and 10 μg G)
Number of subjects: 1155

Group type: COMPARATOR
Intervention: BDP/FF (100 μg BDP and 6 μg FF)
Number of subjects: 1155

Group type: COMPARATOR
Intervention: BDP/FF (200 μg BDP and 6 μg FF)
Number of subjects: 1155
Study: 30380770

Group type: EXPERIMENTAL
Intervention: Test breads with varying amounts of sourdough (9-51% of dough weight) and rye (35-48% of flour weight)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Refined wheat control bread
Number of subjects: 23
Study: 27241922

Group type: EXPERIMENTAL
Intervention: Completion hysterectomy after chemo-radiation (Group B)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard treatment (Group A)
Number of subjects: 150
Study: 25293893

Group type: EXPERIMENTAL
Intervention: Minimally invasive percutaneous compression plating (PCCP)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Dynamic hip screw (DHS)
Number of subjects: 121
Study: 22773165

Group type: EXPERIMENTAL
Intervention: 10 mg JNJ-37822681 (twice daily for 13 doses)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Single dose of JNJ-37822681
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Multiple doses of JNJ-37822681
Number of subjects: 12
Study: 20605012

Group type: EXPERIMENTAL
Intervention: Familiarization with ecological sounds
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjustment task for sound rate memory
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recognition of event rate vs. duration
Number of subjects: 0
Study: 17852440

Group type: EXPERIMENTAL
Intervention: Epoetin alfa (rHuEPO) administered at a dose of 450 IU/kg, once weekly, subcutaneously for 12 weeks.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Epoetin alfa (rHuEPO)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no epoetin alfa)
Number of subjects: 60
Study: 16117460

Group type: EXPERIMENTAL
Intervention: Synthesis coated oxygenators
Number of subjects: 108

Group type: COMPARATOR
Intervention: Monolyth Pro oxygenators (Control)
Number of subjects: 108
Study: 12743129

Group type: EXPERIMENTAL
Intervention: Docetaxel plus carboplatin (DC)
Number of subjects: 1077

Group type: COMPARATOR
Intervention: Paclitaxel plus carboplatin (PC)
Number of subjects: 1077
Study: 11294130

Group type: EXPERIMENTAL
Intervention: Fibre supplement (initial dose of 6 g and maintenance dose of 4 g)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Fibre supplement and reduced energy intake
Number of subjects: 53

Group type: COMPARATOR
Intervention: Reduced energy intake (without fibre)
Number of subjects: 53
Study: 8872406

Group type: EXPERIMENTAL
Intervention: Supraliminal stimulation (A)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Liminal stimulation (B)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Lidocaine (3 mg/kg i.v.) with liminal stimulation (C)
Number of subjects: 65

Group type: COMPARATOR
Intervention: All groups after completed series of treatments
Number of subjects: 65

Group type: COMPARATOR
Intervention: All groups after four treatments
Number of subjects: 65